

| | |
|--|---|
| ❖ Name & Designation | : Mr. Debasmita Dutta, JRF |
| ❖ Address | : Cancer Biology and Inflammatory Disorder Division, CSIR-IICB, 4 Raja S.C. Mullick Road, Jadavpur, Kolkata-700032. |
| ❖ Name of the International Conference/ Seminar/Symposium/Workshop | : 23 rd Biennial Congress of the European Association for cancer research-2014. |
| ❖ Title of the abstract accepted | : A potent betulenenic acid analogue induces apoptosis in HT 29 cells. |
| ❖ Date & Venue | : 5-8 th July, 2014. Munich, Germany. |
| ❖ Money sanctioned | : Rs 70,505/- |
| ❖ Money reimbursed | : Rs 70,505/- |

Participation Report

23rd Biennial Congress of the European Association for Cancer Research is one of the most important cancer meetings in the world. Almost 80 Countries were participated in this conference and there was 7-8 sessions in each day.

EACR mainly focused on basic and discovery driven translational cancer research, bridging the laboratory and the clinic, aiming at converting new knowledge into a reality at the patient level. EACR 23 provided the discussion forum for scientists in all fields of cancer research to discussion, debate and exchange cutting edge discovery as well as offered a series of teaching lectures and workshops focused on noble technologies. There was a wonderful exhibition session from different biological companies to show new instruments, new useful experimental kits. Discussion sessions for analysis and interpretation of high throughput data and its readiness for application within early clinical trials were also a key elements of congress. Our ongoing research work undoubtedly got some new novel ideas to throw light on a new dimension of cancer research leading to development of very effective anti-cancer drug for the benefit of the society at large.

Participant's contribution

I, Debasmita Dutta have participated and presented my poster in poster section at 23rd Biennial Congress of the European Association for Cancer Research which definitely highlight the possibility of the new molecule which can be used as a base for Cancer drug development. I got the opportunity to present my work in front of the eminent scientists of the globe and acquire more knowledge on the cancer biology then that will help CSIR-IICB as well as myself to highlight the new direction in Cancer Drug Development.